Role of Cardiac Contractility Modulation in Heart Failure With a Higher Ejection Fraction

Area of Science:

• Cardiology
• Biomedical Engineering
• Medical Devices

Background:

• Cardiac contractility modulation (CCM) is a novel device therapy for heart failure (HF).
• CCM delivers nonexcitatory electrical stimulation to cardiac myocytes during their absolute refractory period.
• Current guidelines recommend CCM for specific advanced heart failure with reduced ejection fraction (HFrEF) patients.

Purpose of the Study:

• To review the basis of CCM therapy.
• To discuss the potential of CCM for managing patients with higher ejection fraction HF.
• To explore CCM's benefits in HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF).

Main Methods:

• Review of existing experimental and clinical studies on CCM therapy.
• Analysis of CCM's effects on cardiac myocytes and patient outcomes.
• Exploration of CCM's potential in different HF phenotypes.

Main Results:

• CCM therapy improves functional status and clinical outcomes in HFrEF.
• Evidence supports CCM benefits in HFrEF with higher ejection fractions and HFmrEF.
• Experimental studies show CCM can reverse pathological changes in HFpEF.

Conclusions:

• CCM therapy shows promise beyond traditional HFrEF indications.
• Further research may establish CCM as a viable treatment for HFpEF and HFmrEF.
• CCM therapy has the potential to expand its role in comprehensive HF management.